Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of ONO-2506PO in Amyotrophic Lateral Sclerosis
2004-002912-27Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arundic acid in amyotrophic lateral sclerosis (ALS), sponsored by Ono Pharmaceutical. Primary endpoint: Long-term safety of ONO-2506PO. Started Apr 2005; status: completed.
02
Drugs
arundic acid
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2004-002912-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002912-27.